Insulin × glycemic control

TrialBMJ open2016

Metformin versus placebo in combination with insulin analogues in patients with type 2 diabetes mellitus-the randomised, blinded Copenhagen Insulin and Metformin Therapy (CIMT) trial.

Louise Lundby-Christensen et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 412 people · 2016

Randomised comparison

Probably lowered glycemic control

−0.42percentage points−0.62 to −0.23

As reported

difference −0.42 %, 95% CI −0.62 to −0.23

Randomised comparison

Probably lowered body weight & composition

−2.60kg−3.30 to −1.80

As reported

difference −2.6 kg, 95% CI −3.30 to −1.80

Two numbers in the abstract

the abstract, start to end

group (between-group difference -0.42% (95% CI -0.62% to -0.23%),

less weight (between-group difference -2.6 kg (95% CI -3.3 to -1.8),

← favours treatmentfavours comparator →
could be chance
Glycemic control
−0.42−0.62 to −0.23
Body weight & composition
−2.6−3.30 to −1.80
MetforminInsulinGlycemic controlBody weight & composition

Insulin × glycemic controlhelps?mixed

unlikelylikely
0.500.50 without it

Metformin × glycemic controlhelps?replicated

unlikelylikely
0.840.84 without it

Metformin × body weight & compositionhelps?mixed

unlikelylikely
0.500.50 without it
← favours comparatorfavours treatment →
more certainless certain
1 / 5

22 papers cite it

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
this paperpooled ittrialcites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 26916684